drugset / Trial / NCT04044534

Intranasal Insulin for Posttraumatic Stress Disorder

NCT04044534

Phase 2 Completed 10 enrolled VA Connecticut Healthcare System
RandomizedCrossoverQuadruple-blindTreatment

Summary

To evaluate if intranasal insulin is effective in reducing PTSD symptoms.

Timeline

Start
2024-10-31
Primary completion
2026-05-28
Completion
2026-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 40 iu Intranasal